PCAS: H1 2021 Net Sales
Ecully, July 21, 2021
H1 2021 NET
SALES
PCAS (Euronext Paris: PCA), a
specialist in developing and producing complex molecules for life
sciences and innovative technologies, has announced the publication
of its consolidated net sales as of June 30, 2021.
The PCAS Group had generated consolidated net
sales of €106.3 million as of June 30, 2021, up 1.1% compared
to the same period in the previous financial year (+3.1% at a
constant exchange rate).
In millions of euros |
|
2021 |
|
2020 |
|
% change |
|
2021 At a constant exchange rate |
|
% change |
|
|
|
|
|
|
|
|
|
|
|
Sales
as of 30 June |
|
106.3 |
|
105.1 |
|
1.1% |
|
108.4 |
|
3.1% |
Pharmaceutical
Synthesis |
|
72.4 |
|
72.7 |
|
-0.4% |
|
74.4 |
|
2.4% |
Fine Specialty Chemicals |
|
33.9 |
|
32.4 |
|
4.5% |
|
34.0 |
|
4.7% |
Pharmaceutical Synthesis
The Pharmaceutical Synthesis business in Health
generated sales of €72.4 million, down 0.4% compared to 2020 (up
2.4% at a constant exchange rate). The ongoing recovery in R&D
activities was confirmed in the second quarter, with a significant
increase in call for tender volumes for molecules in clinical
development in various therapeutic areas, for which R&D had
slowed at the beginning of the Covid-19 crisis in 2020. The first
half achievements confirmed budget assumptions, with performance
driven by the activity at Villeneuve-la-Garenne site linked to the
first batches of Estetrol produced for Mithra in the new highly
active pharmaceutical drugs production workshop, and by the
increase in activity at Aramon compared to the first half of 2020.
In contrast, efforts made in response to the Covid-19 health
emergency, in particular the production of hand sanitizer sold
under the Naaha brand, had generated significant sales in the first
half of 2020 which were not repeated on the same scale in the first
half of 2021.
Fine Specialty Chemicals
Net sales of Fine Specialty Chemicals totaled
€33.9 million, up 4.5% compared to 2020 (+4.7% at a constant
exchange rate). All activities improved in the first half of the
year, with a sharp rebound in cosmetics and lubricants markets and
sustained growth in the electronics business. A large number of new
products in the pipeline should enable this trend to continue.
Outlook
As mentioned in our previous press releases
since end-March 2020, the global health crisis relating to the
coronavirus is changing by the day, and there is still a gray area
surrounding its duration, its extent and its effects on companies'
production lines and consumption in general.
The potential impacts in the medium term remain
difficult to anticipate. This crisis still calls for cautious
measures. Due to the exceptional circumstances, the Group has
suspended its financial targets and its strategic business
objectives until the situation becomes clearer.
NEXT FINANCIAL DISCLOSURE:
First half 2021 earnings report, September 9,
2021
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 10% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €194.1 million in 2020 and employs close to 1 100
people in six countries.To find out more about PCAS:
www.pcas.com
PCAS |
NewCap |
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier Financial
communication and investor relation |
Tel.: +33 1 69 79 60 00www.pcas.com |
Tel.: +33 1 44 71 98 53pcas@newcap.eu |
|
|
- PCAS_PR_sales H1 2021_ENG
Grafico Azioni PCAS (EU:PCA)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni PCAS (EU:PCA)
Storico
Da Apr 2023 a Apr 2024